Drug Detail

Information about Motesanib diphosphate

Generic Name	Motesanib diphosphate
IND	AMG 706
Brand Name (US)
Manufacturer	Amgen
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 2
Indications
Overall Strategy	KIT Protein Based
Strategy	Block KIT
Drug Category	KIT/PDGFRA inhibitor VEGFR inhibitor (TKI)

AMG 706 is an oral, multi-kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and c-kit receptors intending to inhibit angiogenesis and tumor growth. Amgen is investigating whether targeting all of these receptors could have a multifaceted effect in various tumors. A Phase 2 clinical study evaluating AMG 706 monotherapy in imatinib-resistant GIST and a Phase 2 trial in advanced thyroid cancer have completed enrollment.

AMG 706 is also being developed in combination with multiple chemotherapy regimens in the treatment of solid tumors. Phase 1b studies are ongoing in BC, CRC, NSCLC, and other solid tumors, evaluating various doses and schedules of AMG 706. Some of these studies are evaluating combination therapy of AMG 706 and panitumumab.